FDA Approves Elarek: New Option for Osteoporosis Prevention
Elarek has received FDA approval as a new preventive treatment for osteoporosis, marking a significant advancement in bone health management.
The U.S. Food and Drug Administration (FDA) approved Elarek (lasofoxifene) in 2026 as a new selective estrogen receptor modulator (SERM) for preventing osteoporosis in postmenopausal women at high fracture risk. The approval follows Phase III data showing 42% reduction in vertebral fractures.
Contents11 sections
Key Takeaways
- FDA approved Elarek (lasofoxifene) in 2026 for osteoporosis prevention in high-risk postmenopausal women, based on the PEARL trial (NCT00141323).
- Lasofoxifene 0.5 mg reduced vertebral fractures by 42% (HR 0.58; 95% CI 0.47–0.70) and nonvertebral fractures by 24% (HR 0.76; 95% CI 0.64–0.91) versus placebo.
- The PEARL study enrolled 8,556 postmenopausal women with osteoporosis over a 5-year treatment period.
- Common side effects include hot flashes, leg cramps, and increased venous thromboembolism risk—typical SERM class effects.
- As a third-generation SERM, Elarek acts as an estrogen agonist in bone and antagonist in breast/uterine tissues.
What Is Elarek and How Does It Work?
Elarek (lasofoxifene) is a third-generation selective estrogen receptor modulator (SERM) developed by Sermonix Pharmaceuticals. SERMs are tissue-selective compounds that produce estrogen-like effects in some tissues while blocking estrogen effects in others.
Lasofoxifene functions as an estrogen receptor agonist in bone tissue, helping preserve bone density and reduce fracture risk. In breast and uterine tissues, it acts as an estrogen antagonist, potentially reducing estrogen-related cancer risks. This dual mechanism distinguishes SERMs from bisphosphonates, which work by inhibiting bone-resorbing osteoclasts.
What Did the PEARL Trial Show?
The PEARL trial (Postmenopausal Evaluation and Risk Reduction with Lasofoxifene) was a randomized, double-blind, placebo-controlled Phase III study that enrolled 8,556 postmenopausal women with osteoporosis. Participants received either lasofoxifene 0.25 mg, lasofoxifene 0.5 mg, or placebo daily for five years.
The primary efficacy findings for the 0.5 mg dose, published in the New England Journal of Medicine, demonstrated:
| Fracture Type | Risk Reduction | Hazard Ratio (95% CI) |
|---|---|---|
| Vertebral fractures | 42% | 0.58 (0.47–0.70) |
| Nonvertebral fractures | 24% | 0.76 (0.64–0.91) |
| Hip fractures | Significant reduction | Consistent with overall benefit |
Bone mineral density improved significantly at the lumbar spine and femoral neck compared to placebo. The trial also observed reductions in estrogen receptor-positive breast cancer, coronary heart disease events, and stroke with the 0.5 mg dose.
What Are the Side Effects and Safety Considerations?
Safety data from the PEARL trial confirmed adverse events consistent with the SERM class. The most common side effects included:
- Hot flashes – reported more frequently than with placebo
- Leg cramps – typically mild to moderate
- Venous thromboembolism – increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE)
Importantly, unlike systemic hormone replacement therapy, lasofoxifene did not increase the risk of endometrial hyperplasia in clinical trials. This represents a key safety advantage over unopposed estrogen therapy.
Cardiovascular outcomes in the PEARL trial suggested a potentially favorable profile compared to older SERMs, with reduced risk of coronary events and stroke at the 0.5 mg dose. However, clinicians should monitor patients for thromboembolic events, particularly those with additional risk factors.
Who Is the Ideal Candidate for Elarek?
Elarek is approved for postmenopausal women at high risk of fracture, including:
- Women with diagnosed osteoporosis (T-score ≤ -2.5)
- Women with low bone mass (osteopenia) and additional risk factors
- Those who may benefit from SERM therapy specifically
Patients with a history of venous thromboembolism should not receive Elarek. Candidates should discuss their complete medical history with their healthcare provider, including any cardiovascular risk factors or history of blood clots.
How Does Elarek Compare to Other Osteoporosis Treatments?
Elarek enters a competitive therapeutic area with multiple established options:
- Bisphosphonates (alendronate, risedronate, zoledronic acid) – first-line oral/IV options that inhibit bone resorption
- Denosumab – monoclonal antibody administered every 6 months via injection
- Romosozumab – newer monoclonal antibody that both increases bone formation and decreases resorption
- Raloxifene – older SERM with similar but less robust fracture data
Lasofoxifene's differentiation lies in its tissue-selective mechanism. Unlike bisphosphonates, which uniformly inhibit bone resorption, SERMs work through estrogen pathways. The PEARL trial data suggest lasofoxifene may offer cardiovascular benefits not demonstrated with raloxifene, though direct head-to-head comparisons are limited.
What Is the Regulatory History of Lasofoxifene?
Lasofoxifene's path to FDA approval spanned nearly two decades. Pfizer initially submitted New Drug Applications (NDAs) in 2004 and 2005 for osteoporosis prevention and vaginal atrophy treatment, but these were not approved due to concerns about endometrial safety.
A subsequent NDA (22-242) submitted in 2008 for the 0.5 mg dose garnered a positive FDA Advisory Committee vote, with the panel concluding benefits outweighed risks for the indicated population. However, final approval was delayed.
In March 2009, the European Medicines Agency approved lasofoxifene under the brand name Fablyn for treating osteoporosis in postmenopausal women at increased fracture risk. The 2026 FDA approval of Elarek finally brings this therapy to the U.S. market through Sermonix Pharmaceuticals.
Frequently Asked Questions
What is Elarek and when did it receive FDA approval?
Elarek (lasofoxifene) is a third-generation selective estrogen receptor modulator (SERM) that received FDA approval in 2026 for the prevention of osteoporosis in postmenopausal women at high risk of fracture. It is developed by Sermonix Pharmaceuticals.
How effective is Elarek at reducing fracture risk?
In the Phase III PEARL trial, lasofoxifene 0.5 mg/day reduced vertebral fractures by 42% (HR 0.58; 95% CI 0.47–0.70) and nonvertebral fractures by 24% (HR 0.76; 95% CI 0.64–0.91) compared to placebo in postmenopausal women with osteoporosis.
What are the most common side effects of Elarek?
Common adverse events include hot flashes, leg cramps, and an increased risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism), consistent with SERM class effects. Unlike hormone replacement therapy, lasofoxifene does not increase endometrial hyperplasia risk.
Who should consider taking Elarek for osteoporosis?
Elarek is indicated for postmenopausal women at high risk of fracture, including those with diagnosed osteoporosis or low bone mass. Candidates should have no contraindications to increased venous thromboembolism risk, such as a history of deep vein thrombosis or pulmonary embolism.
How does Elarek compare to other osteoporosis treatments?
Unlike bisphosphonates that inhibit bone resorption, Elarek works through estrogen receptor agonism in bone while antagonizing effects in breast and uterine tissues. As a third-generation SERM, it may offer cardiovascular benefits not seen with older SERMs like raloxifene.
Primary Sources
- U.S. Food and Drug Administration. Elarek (lasofoxifene) approval documentation and label information.
- ClinicalTrials.gov. NCT00141323: PEARL - Postmenopausal Evaluation and Risk Reduction with Lasofoxifene. Phase III randomized trial, n=8,556.
- Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in Postmenopausal Women with Osteoporosis. N Engl J Med. 2010;362(8):686-696. doi:10.1056/NEJMoa0808692
- Lasofoxifene Drug Profile. NovaPharmaNews.
- Osteoporosis Disease Profile. NovaPharmaNews.
Related Profiles
Related Coverage
Continue Exploring
Jump into the entities behind this story.
Follow lasofoxifene developments
FDA osteoporosis alerts and lasofoxifene pipeline updates, every Monday.
This article follows our editorial standards. Report a correction via editorial contact.
